T3 Pharmaceuticals (T3 Pharma) has successfully closed a third financing round, raising over 25 million Swiss francs. According to a press release, the financing was co-led…
Emma Bulmer27.07.2020
Congratulations to one of BaseLaunch’s portfolio companies, Polyneuron on their latest milestone: First clinical trial application approval. Wishing you great success with the studies later…
Jérémie Meyer11.05.2020
Anaveon, a Basel-based immuno-oncology biotech, has successfully concluded a Series A financing round led by Syncona, a UK Life Sciences fund, and joined by the…
Jérémie Meyer05.03.2020
Polyneuron Pharmaceuticals, one of our portfolio companies has successfully raised 22.5 million francs in a round of financing. The Basel-based company will use the proceeds…
Jérémie Meyer04.03.2020
The Basel-based biotech company Alentis Therapeutics AG has successfully concluded a CHF 12.5 million Series A financing co-lead by BioMedPartners and BB Pureos Bioventures and joined by…
Jérémie Meyer03.03.2020
T3 Pharma, a spin-off of the University of Basel and one of our portfolio, has raised over $12 million from Boehringer Ingelheim Venture Fund and…
Jérémie Meyer02.03.2020
Basel-based biopharmaceutical Versameb has raised 6.4 million Swiss francs in a Seed C financing round and will put the funds towards expanding its technology platform.…
Jérémie Meyer01.03.2020
T3 Pharmaceuticals is among the winners of this year’s W.A. de Vigier Award. The spin-off from the University of Basel is developing a targeted cancer…
Jérémie Meyer28.05.2019
Leading venture capital firm Sofinnova Partners led the Series A financing, together with New Enterprise Associates, which co-led the round Basel, Switzerland, 28 March 2019–Polyneuron…
Jérémie Meyer28.03.2019
